Table 1.
Antibody Persistence (by Microneutralization [MN] and Hemagglutination Inhibition [HI] Titers) 3 Weeks and 1 Year After 2 Doses of a Nonadjuvanted Whole-Virion or an AS03B-Adjuvanted Split-Virion Monovalent Pandemic Influenza Vaccine, by Age Group
| MN ≥40 |
MN Change Between Time Points |
HI ≥32 |
HI Change Between Time Points |
|||||||
| Age Group, ya | Total No. | 3 wk After 2nd Pandemic Dose | 1 y Laterb | From ≥40 to <40 | From <40 to ≥40 | MN 1 y Later, Geometric Mean (95% CI)b | 3 wk After 2nd Pandemic Dose | 1 y Laterb | From ≥32 to <32 | From <32 to ≥32 |
| Whole-Virion Vaccine | ||||||||||
| <3 | 68 | 56 (82.4) | 22 (32.4) | 35 | 1 | 33.6 (23.8–47.5) | 40 (58.8) | 43 (63.2) | 8 | 11 |
| 3–12 | 91 | 86 (94.5) | 60 (65.9) | 26 | 0 | 66.9 (53.1–84.2) | 82 (90.1) | 72 (79.1) | 14 | 4 |
| All | 159 | 142 (89.3) | 82 (51.6) | 61 | 1 | 49.8 (40.7–61.0) | 122 (76.7) | 115 (72.3) | 22 | 15 |
| AS03B-Adjuvanted Vaccine | ||||||||||
| <3 | 61 | 61 (100) | 61 (100) | 0 | 0 | 411.9 (332.5–510.2) | 61 (100) | 60 (98.4) | 1 | 0 |
| 3–12 | 98 | 98 (100) | 95 (96.9) | 3 | 0 | 287.6 (230.5–358.9) | 98 (100) | 95 (96.9) | 3 | 0 |
| All | 159 | 159 (100) | 156 (98.1) | 3 | 0 | 330.1 (281.3–387.4) | 159 (100) | 155 (97.5) | 4 | 0 |
Unless otherwise specified, data represent No. (%) of children.
Abbreviation: CI, confidence interval.
a
Age groups based on age at original study [3].
b
P < .001 for all comparisons between 1-year values for whole-virion and AS03B-adjuvanted vaccines.